-
公开(公告)号:US07514405B2
公开(公告)日:2009-04-07
申请号:US10388149
申请日:2003-03-13
申请人: Alexandra Lucas , Robert Zhong , D. Grant McFadden
发明人: Alexandra Lucas , Robert Zhong , D. Grant McFadden
CPC分类号: A61K38/55 , A61K2300/00
摘要: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.
摘要翻译: 提供了哺乳动物移植受体中用于治疗移植排斥的组合物和方法。 该方法包括向需要这种治疗的受试者施用治疗有效量的Serp-1,其类似物和其生物活性片段与抗排斥剂如环孢菌素和药学上可接受的载体。 组合物和方法可用于治疗哺乳动物中的急性和慢性同种异体移植物和异种移植物排斥反应。
-
公开(公告)号:US20090221472A1
公开(公告)日:2009-09-03
申请号:US12380063
申请日:2009-02-23
CPC分类号: A61K38/55 , A61K2300/00
摘要: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.
摘要翻译: 提供了哺乳动物移植受体中用于治疗移植排斥的组合物和方法。 该方法包括向需要这种治疗的受试者施用治疗有效量的Serp-1,其类似物和其生物活性片段与抗排斥剂如环孢菌素和药学上可接受的载体。 组合物和方法可用于治疗哺乳动物中的急性和慢性同种异体移植物和异种移植物排斥反应。
-
公开(公告)号:US07906483B2
公开(公告)日:2011-03-15
申请号:US12380063
申请日:2009-02-23
IPC分类号: A61K38/17
CPC分类号: A61K38/55 , A61K2300/00
摘要: Compositions and methods for treating transplant rejection in a mammalian transplant recipient are provided. The method involves administering a therapeutically effective amount of Serp-1, its analogs, and biologically active fragments thereof in combination with an anti-rejection agent, such as cyclosporin, and a pharmaceutically acceptable carrier to a subject in need of such treatment. The compositions and methods are useful for treating acute and chronic allograft and xenograft transplant rejection in mammals.
摘要翻译: 提供了哺乳动物移植受体中用于治疗移植排斥的组合物和方法。 该方法包括向需要这种治疗的受试者施用治疗有效量的Serp-1,其类似物和其生物活性片段与抗排斥剂如环孢菌素和药学上可接受的载体。 组合物和方法可用于治疗哺乳动物中的急性和慢性同种异体移植物和异种移植物排斥反应。
-
公开(公告)号:US5917014A
公开(公告)日:1999-06-29
申请号:US468865
申请日:1995-06-06
申请人: D. Grant McFadden , Alexandra Lucas
发明人: D. Grant McFadden , Alexandra Lucas
IPC分类号: C12N15/09 , A61K38/55 , A61P1/00 , A61P3/08 , A61P9/00 , A61P11/00 , A61P29/00 , A61P37/00 , A61P43/00 , C07K14/81 , C12P21/02 , A61K38/16
CPC分类号: A61K38/55 , C07K14/8121
摘要: Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1, SERP-1 analog or biologically active fragment thereof admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. Biologically active SERP-1 analogs are also provided. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.
-
公开(公告)号:US5939525A
公开(公告)日:1999-08-17
申请号:US411043
申请日:1995-03-27
申请人: D. Grant McFadden , Alexandra Lucas
发明人: D. Grant McFadden , Alexandra Lucas
IPC分类号: C12N15/09 , A61K38/55 , A61P1/00 , A61P3/08 , A61P9/00 , A61P11/00 , A61P29/00 , A61P37/00 , A61P43/00 , C07K14/81 , C12P21/02 , A61K38/16
CPC分类号: A61K38/55 , C07K14/8121
摘要: Compositions and methods for treating inflammatory cell infiltration in a tissue of a mammalian subject are provided. The method involves administering a therapeutically effective amount of SERP-1, SERP-1 analog or biologically active fragment thereof admixed with a pharmaceutically acceptable carrier to a subject in need of such treatment. Biologically active SERP-1 analogs are also provided. The compositions and methods of the present invention are useful for treating numerous inflammatory based diseases and injuries.
摘要翻译: 提供了用于治疗哺乳动物受试者组织中的炎性细胞浸润的组合物和方法。 该方法包括给予需要这种治疗的受试者施用治疗有效量的与药学上可接受的载体混合的SERP-1,SERP-1类似物或其生物活性片段。 还提供了生物活性的SERP-1类似物。 本发明的组合物和方法可用于治疗许多基于炎症的疾病和损伤。
-
公开(公告)号:US5686409A
公开(公告)日:1997-11-11
申请号:US232238
申请日:1994-05-02
申请人: D. Grant McFadden , Alexandra Lucas
发明人: D. Grant McFadden , Alexandra Lucas
IPC分类号: A61K38/55 , A61K38/00 , A61P9/00 , A61P9/10 , A61P13/02 , A61P15/00 , C07K14/065 , C07K14/81 , A61M31/00 , C07K14/00
CPC分类号: C07K14/8121 , A61K38/00
摘要: A method of treating primary and recurrent atheromatous plaque development is provided. The method involves administering a therapeutically effective amount of SERP-1, admixed in a pharmaceutically acceptable carrier to the intimal or lumenal layer of arterial walls. Biologically active SERP-1 analogs are also provided.
摘要翻译: PCT No.PCT / US94 / 03895 Sec。 371日期:1994年5月2日 102(e)日期1994年5月2日PCT 1994年4月8日PCT PCT。 WO95 / 27503 PCT出版物 日期1995年10月18日提供治疗原发性和复发性动脉粥样硬化斑块发展的方法。 该方法包括将治疗有效量的在药学上可接受的载体中混合的SERP-1施用于动脉壁的内膜或内腔层。 还提供了生物活性的SERP-1类似物。
-
公开(公告)号:US20110288004A1
公开(公告)日:2011-11-24
申请号:US12993191
申请日:2007-06-21
IPC分类号: A61K38/16 , C12N15/63 , C12N5/10 , C12P21/00 , C07K14/065 , A61P29/00 , A61P11/00 , A61P27/14 , A61P17/00 , A61P11/06 , A61P9/00 , A61P9/10 , A61P25/00 , A61P3/10 , A61P13/12 , A61P35/02 , A61P25/28 , A61P19/02 , A61P7/06 , A61P35/00 , C07H21/00 , C07K19/00 , A61K31/7088 , A61P37/02 , A61P17/10 , A61P37/04 , A61P11/02 , A61P37/06 , A61P1/16 , A61P1/18 , A61P1/00 , A61P43/00 , C12N5/09
CPC分类号: A61K48/00 , A61K38/162 , C07K14/005 , C07K2319/02 , C07K2319/21 , C07K2319/41 , C12N2710/24022 , Y02A50/463
摘要: The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein. Finally, the invention features fusion proteins including the myxoma virus T7 signal sequence.
摘要翻译: 本发明的特征在于基于134R序列的多肽和多核苷酸序列。 在一些实施方案中,这些序列包括异源信号序列,例如粘液瘤病毒T7信号序列。 本发明还涉及使用本文所述的多肽和核苷酸治疗免疫疾病和赘生物(例如癌症)的方法。 最后,本发明的特征是融合蛋白包括粘液瘤病毒T7信号序列。
-
-
-
-
-
-